Frontiers in Cell and Developmental Biology (Nov 2024)

Representing ECM composition and EMT pathways in gastric cancer using a new metastatic gene signature

  • Francesco Albano,
  • Francesco Albano,
  • Francesco Albano,
  • Sabino Russi,
  • Simona Laurino,
  • Pellegrino Mazzone,
  • Giuseppina Di Paola,
  • Pietro Zoppoli,
  • Elena Amendola,
  • Elena Amendola,
  • Chiara Balzamo,
  • Ottavia Bartolo,
  • Mario Ciuffi,
  • Orazio Ignomirelli,
  • Alessandro Sgambato,
  • Alessandro Sgambato,
  • Rocco Galasso,
  • Mario De Felice,
  • Mario De Felice,
  • Geppino Falco,
  • Geppino Falco,
  • Giovanni Calice

DOI
https://doi.org/10.3389/fcell.2024.1481818
Journal volume & issue
Vol. 12

Abstract

Read online

IntroductionGastric cancer (GC) is an aggressive and heterogeneous malignancy marked by cellular and molecular diversity. In GC, cancer cells invade locally in the stomach at stage I and can progress to metastasis in distant organs by stage IV, where it often becomes fatal.MethodsWe analyzed gene expression profiles from 719 stage I and stage IV GC patients across seven public datasets, conducting functional enrichment analysis to identify a gene signature linked to disease progression. Additionally, we developed an in vitro model of a simplified extracellular matrix (ECM) for cell-based assays.ResultsOur analysis identified a progression-associated gene signature (APOD, COL1A2, FSTL1, GEM, LUM, and SPARC) that characterizes stage IV GC. This signature is associated with ECM organization and epithelial-to-mesenchymal transition (EMT), both of which influence the tumor microenvironment by promoting cell invasion and triggering EMT.DiscussionThis gene signature may help identify stage I GC patients at higher risk, offering potential utility in early-stage patient management. Furthermore, our experimental ECM model may serve as a platform for investigating molecular mechanisms underlying metastatic spread in gastric cancer.

Keywords